FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

	OMB APPRO	VAL			
	OMB Number:	3235-028			
Estimated average burden					
	houre per reenonce	0			

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. *See* Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Typ	e Responses)														
1. Name and Address of Reporting Person – TAGLIAFERRI MARY					2. Issuer Name and Ticker or Trading Symbol ENZO BIOCHEM INC [ENZ]							5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner				
(Last) (First) (Middle) C/O ENZO BIOCHEM, INC., 527 MADISON AVENUE				3. Date of Earliest Transaction (Month/Day/Year) 01/11/2021								Officer (give title below) Other (specify below))
(Street) NEW YORK, NY 10022				4. If Amendment, Date Original Filed(Month/Day/Year)						_X_ For	6. Individual or Joint/Group Filing(Check Applicable Line) X_ Form filed by One Reporting Person Form filed by More than One Reporting Person					
NEW YO		(State)	(Zip)				Tab	la I - Nan-Da	rivativa	Sacurities	Acquired F	tienoead a	f or Ronofic	rially Owned		
1.Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Yea			2A. Deemed Execution Date any		d 3. Tra		ransaction e	4. Secur (A) or D	Securities Acquired A) or Disposed of (D) Instr. 3, 4 and 5)		5. Amount of Sec Owned Followin Transaction(s)		eficially	Ownership Form:	7. Nature of Indirect Beneficial	
				(Month/E		y/Year)	C	ode V	Amount	(A) or (D)	(Instr.	3 and 4)			Direct (D) or Indirect I) Instr. 4)	Ownership Instr. 4)
											ed to respondent		ss the forn	n displays a		
			Table II	- Deriv	ative (Securiti	os A	this fo	ntly vali	d OMB co	ntrol numb	er.	ss the forn	n displays a		
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if	(e.g.,] 4. Transac Code	tion S	e <mark>alls, wa</mark> 5. Numb	er ative	this fo curred cquired, Dis ts, options, o	oosed of, convertible reisable a	d OMB co or Benefic ble securitie	ntrol numb	Amounting	8. Price of Derivative Security (Instr. 5)	9. Number o		
Derivative Security	Conversion or Exercise	Date	3A. Deemed Execution Date, if any	(e.g.,] 4. Transac Code	outs, c	calls, was 5. Numb of Deriva Securitie	er ative s d (A) sed	this fo curred equired, Dis ts, options, o 6. Date Exe Expiration I	oosed of, convertible reisable a	d OMB co or Benefic ble securitie	ially Owned of Underly Securities	Amounting	8. Price of Derivative Security	9. Number o Derivative Securities Beneficially Owned Following Reported Transaction(Owners Form of Derivati Security Direct (I or Indirects)	of Indirect Beneficia Ownershi (Instr. 4)
Derivative Security	Conversion or Exercise Price of Derivative	Date	3A. Deemed Execution Date, if any	(e.g.,] 4. Transac Code	outs, c	5. Numb of Deriva Securitie Acquired or Dispo of (D) (Instr. 3,	er ative s d (A) sed	this fo curred equired, Dis ts, options, o 6. Date Exe Expiration I	ntly validosed of, convertible recisable and convertible and c	or Beneficole securities	ially Owned of Underly Securities	Amounting	8. Price of Derivative Security	9. Number o Derivative Securities Beneficially Owned Following Reported	Owners Form of Derivati Security Direct (I or Indire	of Indirect Beneficia Ownershi (Instr. 4)

Reporting Owners

	Relationships					
Reporting Owner Name / Address	Director	10% Owner	Officer	Other		
TAGLIAFERRI MARY C/O ENZO BIOCHEM, INC. 527 MADISON AVENUE NEW YORK, NY 10022	X					

Signatures

/s/ Mary Tagliaferri	01/13/2021
**Signature of Reporting Person	Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The Reporting Person was granted 77,101 stock options. The stock options have a five-year term and 50% of the stock options will vest on the first anniversary of the grant date and 50% on the second anniversary of the grant date.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.